转化医学杂志2025，Vol.14Issue(1)：273-276,4.DOI:10.3639/i.issn.2095-3097.2025.01.054
鲁索替尼治疗白癜风的研究进展
Research Progress of Ruxolitinib in the Treatment of Vitiligo
李朝宇 1张洪英2
作者信息
- 1. 261053 山东潍坊,山东第二医科大学临床医学院
- 2. 266011 山东青岛,青岛市市立医院皮肤科
- 折叠
摘要
Abstract
Vitiligo is an autoimmune skin disease caused by abnormal function of melanocytes in white spots.The pathogenesis of vitiligo is still unclear.Current research has found that the Janus kinase-signal transducer and activator of transcription(JAK-STAT)signaling pathway is involved in the pathogenesis of vitiligo.Ruxolitinib is a typical JAK inhibitor that mainly acts on the JAK-STAT signaling pathway and plays an important role in inhibiting inflammation,and regulating immune and hematopoietic function.Domestic and foreign studies have shown that ruxolitinib has clear efficacy in skin diseases,such as atopic dermatitis and alopecia areata,showing good application prospects in the treatment of vitiligo.This article mainly summarized the latest research progress of ruxolitinib in the treatment of vitiligo.关键词
鲁索替尼/白癜风/酪氨酸蛋白激酶/转导因子和转录激活因子Key words
Ruxolitinib/Vitiligo/Tyrosine protein kinase/Transduction factors and transcriptional activators分类
医药卫生引用本文复制引用
李朝宇,张洪英..鲁索替尼治疗白癜风的研究进展[J].转化医学杂志,2025,14(1):273-276,4.
